{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:14:24Z","timestamp":1783779264714,"version":"3.55.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,5]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>This study aimed to identify adverse drug reaction (ADR) risk signals associated with budesonide\/glycopyrrolate\/formoterol (Breztri) and fluticasone furoate\/umeclidinium\/vilanterol (Trelegy Ellipta) to support clinical decision-making and risk management. ADR reports related to Breztri and Trelegy Ellipta from the FDA Adverse Event Reporting System (FAERS) database, Japanese Adverse Drug Event Report (JADER) database and Canada Vigilance Adverse Reaction database (Q3 2004 to Q2 2024) were analyzed. After deduplication, reports were categorized using Medical Dictionary for Regulatory Activities (MedDRA) to obtain System Organ Class (SOC) and preferred terms (PTs). Disproportionality analysis was conducted using reporting odds ratio (ROR) and proportional reporting ratio methods. Analysis of 394 Breztri and 18,866 Trelegy Ellipta FAERS reports (predominantly consumer-submitted, U.S.-originated) identified 47 signals across 11 SOCs for Breztri (e.g., \u201cDrug delivery system issue\u201d ROR\u2005=\u2005411.16, \u201cIntentional device misuse\u201d ROR\u2005=\u2005410.69) and 160 signals across 15 SOCs for Trelegy (e.g., \u201cChronic eosinophilic rhinosinusitis\u201d ROR\u2005=\u2005187.65, \u201cForeign body in mouth\u201d ROR\u2005=\u2005107.67), revealing unlabeled risks like administration errors and packaging confusion. JADER data reinforced respiratory risks (Breztri: Chronic obstructive pulmonary disease (COPD) ROR\u2005=\u2005516.8; Trelegy: gastrointestinal fungal infection ROR\u2005=\u2005413.11) and device-independent safety signals (e.g., Trelegy urinary retention ROR\u2005=\u200528.81), while CVARD highlighted region-specific concerns including Trelegy-associated vasculitis (pulmonary vasculitis n\u2005=\u200529) and Breztri hypertension (ROR\u2005=\u20057.82). Cross-database convergence confirmed core anticholinergic\/cardiopulmonary risks, yet divergent signals, FAERS\u2019 device errors, JADER\u2019s infection prominence, and CVARD\u2019s immunological events, underscore geographic heterogeneity in adverse reaction profiles, necessitating tailored risk management strategies for inhaler therapies. Inhalation device-related ADRs were observed, with Breztri showing higher incidence than Trelegy Ellipta, likely due to its more complex device usage. These findings highlight the need for enhanced patient education by healthcare providers to ensure proper device use in COPD treatment. Although core respiratory and anticholinergic risks are globally relevant, infection profiles, device complications, and rare immunological events exhibit significant geographic heterogeneity, necessitating tailored risk mitigation strategies aligned with regional pharmacovigilance patterns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049162","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:00:56Z","timestamp":1780718456000},"page":"e49162","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Adverse event mining for Breztri and Trelegy Ellipta based on the three international pharmacovigilance databases"],"prefix":"10.1097","volume":"105","author":[{"given":"Junyu","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1026-1661","authenticated-orcid":false,"given":"Dexiang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260711","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/ACI.0000000000000920","article-title":"COPD and biologic treatment: state of the art.","volume":"23","author":"Ferri","year":"2023","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R2-20260711","doi-asserted-by":"crossref","first-page":"14523","DOI":"10.1038\/s41598-024-64908-6","article-title":"Associations of ethylene oxide exposure with depression in American adults.","volume":"14","author":"Wang","year":"2024","journal-title":"Sci Rep"},{"key":"R3-20260711","first-page":"43","article-title":"12-month prevalence of known chronic obstructive pulmonary disease (COPD) in Germany.","volume":"2","author":"Steppuhn","year":"2017","journal-title":"J Health Monit"},{"key":"R4-20260711","first-page":"CD011594","article-title":"Combined aclidinium bromide and long\u2010acting beta2\u2010agonist for chronic obstructive pulmonary disease (COPD).","volume":"12","author":"Ni","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-20260711","first-page":"CD008989","article-title":"Long-acting beta(2)\u2010agonist in addition to tiotropium versus either tiotropium or long\u2010acting beta(2)\u2010agonist alone for chronic obstructive pulmonary disease.","volume":"4","author":"Karner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R6-20260711","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1378\/chest.125.1.249","article-title":"The role of long-acting bronchodilators in the management of stable COPD.","volume":"125","author":"Tashkin","year":"2004","journal-title":"Chest"},{"key":"R7-20260711","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"key":"R8-20260711","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1465-9921-11-149","article-title":"Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.","volume":"11","author":"Tashkin","year":"2010","journal-title":"Respir Res"},{"key":"R9-20260711","first-page":"253","article-title":"Guideline for the diagnosis and treatment of COPD patients-issued by the German Respiratory Society and the German Atemwegsliga in cooperation with the Austrian Society of Pneumology.","volume":"72","author":"Vogelmeier","year":"2018","journal-title":"Pneumologie (Stuttgart, Germany)"},{"key":"R10-20260711","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1111\/bcp.14671","article-title":"Polypharmacy, potentially inappropriate medication and pharmacogenomics drug exposure in the Rhineland Study.","volume":"87","author":"de Vries","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"R11-20260711","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.2147\/COPD.S279193","article-title":"Use of web-based videos in a community pharmacy to optimize inhalation technique.","volume":"15","author":"M\u00fcller","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"R12-20260711","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-018-0936-3","article-title":"Use and inhalation technique of inhaled medication in patients with asthma and COPD: data from a randomized controlled trial.","volume":"19","author":"Gregoriano","year":"2018","journal-title":"Respir Res"},{"key":"R13-20260711","first-page":"15","article-title":"Interpretation of 2018 GOLD Global strategy for Diagnosis, treatment and prevention of chronic obstructive pulmonary disease.","volume":"9","author":"Chen","year":"2017","journal-title":"Chin Med Front J"},{"key":"R14-20260711","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3329\/kyamcj.v7i2.33842","article-title":"Dual bronchodilation by once daily fixed dose combined indacaterol and glycopyrronium, new era for treatment in moderate to severe COPD.","volume":"7","author":"Uddin","year":"2017","journal-title":"KYAMC J"},{"key":"R15-20260711","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1164\/rccm.200703-456SO","article-title":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary.","volume":"176","author":"KF","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"R16-20260711","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1208\/s12248-007-9004-5","article-title":"Informatic tools and approaches in postmarketing pharmacovigilance used by FDA.","volume":"10","author":"Weaver","year":"2008","journal-title":"AAPS J"},{"key":"R18-20260711","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2125.2003.01968.x","article-title":"Application of data mining techniques in pharmacovigilance.","volume":"57","author":"Wilson","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R19-20260711","doi-asserted-by":"crossref","first-page":"107498","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system.","volume":"95","author":"Chen","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"R20-20260711","doi-asserted-by":"crossref","first-page":"e13331","DOI":"10.1111\/ijcp.13331","article-title":"Assessing fluoroquinolone\u2010associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system.","volume":"73","author":"Meng","year":"2019","journal-title":"Int J Clin Pract"},{"key":"R21-20260711","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A Disproportionality analysis for DrUg safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration.","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"R22-20260711","first-page":"380","article-title":"The application of several signal monitoring methods in adverse drug events was briefly analyzed.","volume":"30","author":"Dai","year":"2012","journal-title":"J Pharm Pract"},{"key":"R24-20260711","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMra1900500","article-title":"Update on clinical aspects of chronic obstructive pulmonary disease.","volume":"381","author":"Celli","year":"2019","journal-title":"N Engl J Med"},{"key":"R25-20260711","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1007\/s12325-022-02231-0","article-title":"Fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) triple therapy compared with other therapies for the treatment of COPD: a network meta-analysis.","volume":"39","author":"Ismaila","year":"2022","journal-title":"Adv Ther"},{"key":"R26-20260711","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD.","volume":"383","author":"Rabe","year":"2020","journal-title":"N Engl J Med"},{"key":"R27-20260711","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1183\/09059180.00003609","article-title":"Epidemiology of COPD.","volume":"18","author":"Raherison","year":"2009","journal-title":"Eur Respiratory Rev"},{"key":"R28-20260711","doi-asserted-by":"crossref","first-page":"JITC17","DOI":"10.7326\/IsTranslatedFrom_AITC202008040_Japanese","article-title":"Chronic obstructive pulmonary disease (Japanese Version).","volume":"173","author":"Labaki","year":"2020","journal-title":"Ann Intern Med"},{"key":"R29-20260711","doi-asserted-by":"crossref","first-page":"104903","DOI":"10.1016\/j.psj.2025.104903","article-title":"Mechanisms of the effects of turpiniae folium extract on growth performance, immunity, antioxidant activity and intestinal barrier function in LPS-challenged broilers.","volume":"104","author":"Song","year":"2025","journal-title":"Poult Sci"},{"key":"R30-20260711","doi-asserted-by":"crossref","first-page":"105938","DOI":"10.1016\/j.rmed.2020.105938","article-title":"Goals of COPD treatment: Focus on symptoms and exacerbations.","volume":"166","author":"Vogelmeier","year":"2020","journal-title":"Respir Med"},{"key":"R31-20260711","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2147\/COPD.S252435","article-title":"Nebulized therapies in COPD: past, present, and the future.","volume":"15","author":"Barjaktarevic","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"R32-20260711","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2147\/COPD.S49392","article-title":"COPD management: role of symptom assessment in routine clinical practice.","volume":"8","author":"van der Molen","year":"2013","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"R33-20260711","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ijtb.2022.06.004","article-title":"Indian Guidelines on nebulization therapy.","volume":"69","author":"Katiyar","year":"2022","journal-title":"Ind J Tuberculosis"},{"key":"R34-20260711","doi-asserted-by":"crossref","first-page":"e018404","DOI":"10.1136\/bmjopen-2017-018404","article-title":"Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study.","volume":"8","author":"Hanlon","year":"2018","journal-title":"BMJ Open"},{"key":"R35-20260711","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/crj.13434","article-title":"Clinical characteristics and outcomes of polypharmacy in chronic obstructive pulmonary disease patients: a cross\u2010sectional study from Crete, Greece.","volume":"15","author":"Ierodiakonou","year":"2021","journal-title":"Clin Respir J"},{"key":"R36-20260711","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1378\/chest.125.6.2309","article-title":"Cardiovascular effects of \u03b2-agonists in patients with asthma and COPD: a meta-analysis.","volume":"125","author":"Salpeter","year":"2004","journal-title":"Chest"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000049162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:01:12Z","timestamp":1783778472000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000049162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":34,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049162","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"2026-01-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}